Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $30.17.

A number of analysts have recently issued reports on CELC shares. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Tuesday, April 1st. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Celcuity in a research report on Tuesday, April 1st.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $8.65 on Friday. The firm has a market capitalization of $321.17 million, a P/E ratio of -3.31 and a beta of 0.44. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $10.99 and its two-hundred day simple moving average is $12.76. Celcuity has a twelve month low of $7.70 and a twelve month high of $20.15.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.13). As a group, equities analysts anticipate that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Summit Investment Advisors Inc. grew its position in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after acquiring an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Celcuity in the fourth quarter worth approximately $50,000. The Manufacturers Life Insurance Company purchased a new position in shares of Celcuity in the fourth quarter worth $142,000. Bleakley Financial Group LLC purchased a new position in shares of Celcuity in the fourth quarter worth $146,000. Finally, Trexquant Investment LP bought a new stake in Celcuity during the 4th quarter valued at $152,000. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.